234 related articles for article (PubMed ID: 35340168)
1. [Immunotherapy for microsatellite-instability-high advanced colorectal cancer].
Ding PR
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):199-204. PubMed ID: 35340168
[TBL] [Abstract][Full Text] [Related]
2. [Organ preservation in locally advanced colorectal cancer with microsatellite instability-high after immunotherapy].
Hong ZG; Xiao BY; Ding PR
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):353-358. PubMed ID: 38644240
[TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant immunotherapy for colorectal cancer].
Pei JP; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001
[TBL] [Abstract][Full Text] [Related]
4. The current status and prospect of immunotherapy in colorectal cancer.
Shu Y; Zheng S
Clin Transl Oncol; 2024 Jan; 26(1):39-51. PubMed ID: 37301804
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X
Front Immunol; 2023; 14():1044353. PubMed ID: 36776899
[TBL] [Abstract][Full Text] [Related]
6. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
7. [Neoadjuvant immunotherapy in microsatellite stability or mismatch repair proficient colorectal cancer].
Zhang JW; Deng YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):193-198. PubMed ID: 35340167
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
9. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract][Full Text] [Related]
10. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
11. Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis.
Toh JWT; Phan K; Reza F; Chapuis P; Spring KJ
Int J Colorectal Dis; 2021 Aug; 36(8):1573-1596. PubMed ID: 33604737
[TBL] [Abstract][Full Text] [Related]
12. Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review.
Xiao B; Yu J; Ding PR
Clin Colon Rectal Surg; 2023 Nov; 36(6):378-384. PubMed ID: 37795463
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment.
Yu JH; Liao LE; Xiao BY; Zhang X; Wu AW; Cheng Y; Tang JH; Jiang W; Kong LH; Han K; Mei WJ; Hong ZG; Yang WJ; Li DD; Pan ZZ; Li YF; Zhang XS; Ding PR
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38498975
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer.
Liu DX; Li DD; He W; Ke CF; Jiang W; Tang JH; Kong LH; Li Y; Sui QQ; Xiao BY; Li WR; Hong ZG; Xu RH; Pan ZZ; Zhang XS; Ding PR
Oncoimmunology; 2020; 9(1):1711650. PubMed ID: 32042474
[No Abstract] [Full Text] [Related]
15. Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
Zhu J; Lian J; Xu B; Pang X; Ji S; Zhao Y; Lu H
Front Immunol; 2023; 14():1120684. PubMed ID: 36949951
[TBL] [Abstract][Full Text] [Related]
16. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
17. [Immune checkpoint inhibitors in the treatment of colorectal cancer: a review of clinical trials].
Gong XL; Zhao L
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):205-213. PubMed ID: 35340169
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study.
Wang QX; Xiao BY; Cheng Y; Wu AW; Zhang T; Wang H; Zhang X; Huang WX; Tang JH; Jiang W; Steele SR; Krishnamurthi S; Li Y; Cai J; Kong LH; Li DD; Pan ZZ; Zhang XS; Ding PR
Eur J Cancer; 2022 Oct; 174():176-184. PubMed ID: 36030556
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of microsatellite instability in colorectal cancer: A review.
Gelsomino F; Barbolini M; Spallanzani A; Pugliese G; Cascinu S
Cancer Treat Rev; 2016 Dec; 51():19-26. PubMed ID: 27838401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
